New recombinant cell line from Crown Bioscience

Crown Bioscience (CrownBio), Crown Bioscience International’s wholly owned subsidiary and a worldwide development services company, recently launched its own six new recombinant cell lines dedicated to drug screening, biological studies, development, and discovery.

The company offers translational platforms to further metabolic and oncology disease research for oncology drug discoveries.

The new lines, with CTLA-4, CD137, ICOS, GITR, OX40, and RANK immune checkpoints and receptors, qualify as crucial pathways and targets that can be used to discover and create oncological drugs, benefitting countless patients around the world.

"We are excited to be offering these new cell lines to researchers and drug development scientists," Abe Couse, VP of the life science division at CrownBio, said. "These recombinant cell lines express enzymes and proteins that can impact immune response, cell proliferation and cell death, and they will help scientists better understand the role of these genes and related pathways to the causes and potential cures for cancer."

The cell lines further expand the company’s life science portfolio, which features a Wnt Luciferase reporter, BCR-ABL Kinase, ALK Kinases, PD-1, EGFR, and PD-L1 cell lines. There are currently 16 of these off-the-shelf recombinant cell lines available for purchase.

"These cell lines provide 'gold standard' services and tools to our clients within preclinical drug discovery," Jean-Pierre Wery, president at CrownBio, said. "Ultimately, we hope to reduce the attrition rate of candidate compounds in the clinic, before they enter the clinic."